A panel of protein kinase high expression is associated with postoperative recurrence in cholangiocarcinoma

BMC Cancer

Table 6 Multivariate analysis of factors predicting recurrence-free survival

Variable	Recurrence-free survival
Variable	HR	95% CI	p
Model A
Primary tumor (T) (III/IV vs I/II)	2.058	1.364–3.104	0.001
Lymph nodes metastasis (N) (Yes vs No)	1.617	1.083–2.413	0.019
TNM Stage (III/IV vs I/II)	1.107	0.654–1.873	0.705
EGFR (High vs Low)	1.542	1.131–2.103	0.006
Model B
Primary tumor (T) (III/IV vs I/II)	2.000	1.312–3.047	0.001
Lymph nodes metastasis (N) (Yes vs No)	1.459	0.963–2.211	0.075
TNM Stage (III/IV vs I/II)	1.158	0.668–2.009	0.601
HER4 (High vs Low)	1.388	1.011–1.906	0.042
Model C
Primary tumor (T) (III/IV vs I/II)	1.977	1.296–3.017	0.002
Lymph nodes metastasis (N) (Yes vs No)	1.467	0.967–2.225	0.071
TNM Stage (III/IV vs I/II)	1.242	0.712–2.168	0.445
EphA3 (High vs Low)	1.469	1.091–1.977	0.011
Model D
Primary tumor (T) (III/IV vs I/II)	1.918	1.255–2.931	0.003
Lymph nodes metastasis (N) (Yes vs No)	1.480	0.979–2.240	0.063
TNM Stage (III/IV vs I/II)	1.193	0.686–2.073	0.531
Protein panel^a (2–3 markers high vs Others^b)	1.528	1.116–2.091	0.008
Model E
Primary tumor (T) (III/IV vs I/II)	3.275	1.710–6.273	3.5 × 10⁻⁴
Lymph nodes metastasis (N) (Yes vs No)	1.749	1.017–3.009	0.043
TNM Stage (III/IV vs I/II)	0.660	0.292–1.496	0.320
Combined of protein panel and CA19–9 level (2–3 markers high and CA19–9 high vs Others^c)	2.080	1.270–3.405	0.004

TNM Size of primary tumor-node metastasis-distant metastasis, EGFR Epidermal growth factor receptor, HER Human epidermal growth factor receptor, EphA3 Erythropoietin-producing hepatocellular carcinoma receptor type-A3, Protein panel^a: the expression of EGFR, HER4 and EphA3, Protein panel^a: the expression of EGFR, HER4 and EphA, Others^b: 0–1 marker high, Others^c: three groups of patients (0–1 marker high and CA19–9 low, 0–1 marker high and CA19–9 high or 2–3 markers high and CA19–9 low)

ISSN: 1471-2407